Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 6/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373197 | 0.90 | HCRTR2 (0.45) | HCRTR2HCRTR1METCLK1MAPK1 | |
| SCHEMBL8087620 | 0.87 | HCRTR1 (0.55) | HCRTR2HCRTR1SMN1; SMN2RPS6KB1MAPK1 | |
| SCHEMBL2279860 | 0.86 | MET (0.43) | HCRTR2HCRTR1METCLK1PDPK1 | |
| SCHEMBL8081046 | 0.83 | HCRTR2 (0.73) | HCRTR2HCRTR1MET | |
| SCHEMBL2277007 | 0.83 | SMN1; SMN2 (0.43) | HCRTR2HCRTR1METSMN1; SMN2CLK1 | |
| SCHEMBL2282140 | 0.82 | KIT (0.49) | HCRTR2HCRTR1CLK1RPS6KB1MAPK1 | |
| SCHEMBL12373198 | 0.76 | HCRTR2 (0.61) | HCRTR2HCRTR1METMAPK1 | |
| SCHEMBL2277917 | 0.76 | HCRTR2 (0.78) | HCRTR2HCRTR1MET | |
| SCHEMBL2280004 | 0.73 | HCRTR2 (0.70) | HCRTR2HCRTR1MET | |
| SCHEMBL2280728 | 0.71 | HCRTR2 (0.61) | HCRTR2HCRTR1METMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | BERGMAN JEFFREY M (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2009020642-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301140-A1 | Pyridine Carboxamide orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY1R | HCRTR2 1/4885HCRTR1 2/4885MET 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.